Loading clinical trials...

Therapeutic Diets in Alzheimer's Disease | Clinical Trials | Clareo Health

COMPLETEDNA

Therapeutic Diets in Alzheimer's Disease

NCT03860792•University of Kansas Medical Center

Summary

By doing this study, researchers hope to learn how the ketogenic and Therapeutic Lifestyles Changes diets affect cognition in patients with Alzheimer's disease.

Eligibility

Age

50 - 90 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Diagnosis of AD by current McKhann et al. criteria
•CDR global score of 0.5 or 1
•Agreed cooperation from an appropriate study partner
•Speaks English as primary language
•Age 50 to 90
•No medication changes within the past 30 days

Exclusion Criteria

•Resides in a nursing home or dementia special care unit, or cannot control diet
•A potentially confounding serious medical risk including insulin-requiring diabetes, cancer requiring chemotherapy or radiation within the past 5 years, or a recent cardiac event (i.e. heart attack, angioplasty, etc.)
•Participating in another clinical trial or using an investigational drug or therapy within 30 days of the Screening Visit
•A history of renal stones

Locations (1)

Clinical and Translational Science Unit

Fairway, Kansas, United States

Key Dates

Start Date

October 15, 2019

Primary Completion Date

May 23, 2025

Completion Date

June 20, 2025

Last Updated

December 17, 2025

Enrollment

ACTUAL participants

Conditions

Alzheimer Disease

Interventions

Ketogenic Diet

BEHAVIORAL

Therapeutic Lifestyles Changes Diet

BEHAVIORAL

Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease

NCT07178210

Alzheimer DiseaseLymphatic Obstruction

View study

RECRUITINGEARLY_PHASE1

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

NCT04123314

Depressive SymptomsDepression+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 17, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Therapeutic Diets in Alzheimer's Disease

Inclusion Criteria

Exclusion Criteria

Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)

Longitudinal Early-onset Alzheimer's Disease Study Protocol

A Study of AMDX-2011P in Participants With Alzheimer's Disease